These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


98 related items for PubMed ID: 7589196

  • 1. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia.
    Reynolds GP, Mason SL.
    Eur J Pharmacol; 1995 Aug 04; 281(2):R5-6. PubMed ID: 7589196
    [Abstract] [Full Text] [Related]

  • 2. Are striatal dopamine D4 receptors increased in schizophrenia?
    Reynolds GP, Mason SL.
    J Neurochem; 1994 Oct 04; 63(4):1576-7. PubMed ID: 7931313
    [Abstract] [Full Text] [Related]

  • 3. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.
    Seeman P, Guan HC, Van Tol HH.
    Eur J Pharmacol; 1995 Nov 14; 286(2):R3-5. PubMed ID: 8605946
    [Abstract] [Full Text] [Related]

  • 4. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
    Seeman P, Guan HC, Van Tol HH, Niznik HB.
    Synapse; 1993 Aug 14; 14(4):247-53. PubMed ID: 8248849
    [Abstract] [Full Text] [Related]

  • 5. Dopamine D4 receptors elevated in schizophrenia.
    Seeman P, Guan HC, Van Tol HH.
    Nature; 1993 Sep 30; 365(6445):441-5. PubMed ID: 8413587
    [Abstract] [Full Text] [Related]

  • 6. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.
    Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY.
    Brain Res; 1995 May 29; 681(1-2):109-16. PubMed ID: 7552267
    [Abstract] [Full Text] [Related]

  • 7. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P.
    Neuropsychopharmacology; 2006 May 29; 31(5):1027-35. PubMed ID: 16237387
    [Abstract] [Full Text] [Related]

  • 8. Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.
    Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY.
    Neuropsychopharmacology; 2005 Dec 29; 30(12):2283-9. PubMed ID: 16123775
    [Abstract] [Full Text] [Related]

  • 9. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.
    Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, Carter JM, Weinberger DR, Kleinman JE.
    J Neurosci; 1995 Mar 29; 15(3 Pt 2):2186-91. PubMed ID: 7891160
    [Abstract] [Full Text] [Related]

  • 10. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains.
    Helmeste DM, Tang SW, Bunney WE, Potkin SG, Jones EG.
    Eur J Pharmacol; 1996 Oct 31; 314(3):R3-5. PubMed ID: 8957266
    [Abstract] [Full Text] [Related]

  • 11. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
    Tang SW, Helmeste DM, Fang H, Li M, Vu R, Bunney W, Potkin S, Jones EG.
    Brain Res; 1997 Aug 08; 765(1):7-12. PubMed ID: 9310388
    [Abstract] [Full Text] [Related]

  • 12. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Bird ED, Riederer P, Jellinger K, Tourtellotte WW.
    Neuropsychopharmacology; 1987 Dec 08; 1(1):5-15. PubMed ID: 2908095
    [Abstract] [Full Text] [Related]

  • 13. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia.
    Joyce JN, Lexow N, Bird E, Winokur A.
    Synapse; 1988 Dec 08; 2(5):546-57. PubMed ID: 2973147
    [Abstract] [Full Text] [Related]

  • 14. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM, Bressan RA, Erlandsson K, Ell PJ, Pilowsky LS.
    Psychopharmacology (Berl); 2005 Aug 08; 180(4):664-9. PubMed ID: 15719226
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptors in schizophrenia.
    Gjedde A, Reith J, Wong D.
    Lancet; 1995 Nov 11; 346(8985):1302-3. PubMed ID: 7475750
    [No Abstract] [Full Text] [Related]

  • 16. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
    Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ.
    Am J Psychiatry; 1996 Feb 11; 153(2):183-90. PubMed ID: 8561197
    [Abstract] [Full Text] [Related]

  • 17. The dopamine D3 receptor and schizophrenia: pharmacological, anatomical and genetic approaches.
    Griffon N, Sokoloff P, Diaz J, Lévesque D, Sautel F, Schwartz JC, Simon P, Costentin J, Garrido F, Mann A.
    Eur Neuropsychopharmacol; 1995 Feb 11; 5 Suppl():3-9. PubMed ID: 8775753
    [Abstract] [Full Text] [Related]

  • 18. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
    Tibbo P, Silverstone PH, McEwan AJ, Scott J, Joshua A, Golberg K.
    J Psychiatry Neurosci; 1997 Jan 11; 22(1):39-45. PubMed ID: 9002391
    [Abstract] [Full Text] [Related]

  • 19. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, Pilowsky LS.
    Am J Psychiatry; 2003 Aug 11; 160(8):1413-20. PubMed ID: 12900302
    [Abstract] [Full Text] [Related]

  • 20. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
    Seeman P, Van Tol HH.
    J Neurochem; 1995 Mar 11; 64(3):1413-5. PubMed ID: 7861175
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.